Mass Spectrometry Imaging; Immunohistochemistry; Pathology
Disciplines :
Biotechnology
Author, co-author :
Longuespée, Rémi ; Université des Sciences et Technologies de Lille - USTL > Sciences Naturelles > Laboratoire de Spectrométrie de Masse Biologique Fondamentale et Appliquée
Boyon, Charlotte
Desmons, Annie
Kerdraon, Olivier
Leblanc, Eric
Farré, Isabelle
Vinatier, Denis
Day, Robert
Fournier, Isabelle
Salzet, Michel
Language :
English
Title :
Spectroimmunohistochemistry: A Novel Form of MALDI Mass Spectrometry Imaging Coupled to Immunohistochemistry for Tracking Antibodies.
Aichler M, Elsner M, Ludyga N, et al. (2013). Clinical response to chemotherapy in oesophageal adenocarcinoma patients is linked to defects in mitochondria. J Pathol 230, 410-419.
Angel PM, and Caprioli RM. (2013). MALDI Imaging Mass Spectrometry: In situ Molecular Mapping. Biochemistry 52, 3818-3828.
Balluff B, Elsner M, Kowarsch A, et al. (2010). Classification of HER2/neu status in gastric cancer using a breast-cancer derived proteome classifier. J Proteome Res 9, 6317-6322.
Balluff B, Rauser S, Meding S, et al. (2011). MALDI imaging identifies prognostic seven-protein signature of novel tissue markers in intestinal-type gastric cancer. Am J Pathol 179, 2720-2729.
Bonnel D., Franck J., Meriaux C., Salzet M., and Fournier I. (2013). Ionic matrices pre-spotted MALDI plates for patients markers following, drugs titration and MALDI MSI. Anal Biochem 434, 187-198.
Bonnel D, Longuespee R, Franck J, et al. (2011). Multivariate analyses for biomarkers hunting and validation through ontissue bottom-up or in-source decay in MALDI-MSI: Application to prostate cancer. Anal Bioanal Chem 401, 149-165.
Caprioli RM, Farmer TB, and Gile J. (1997). Molecular imaging of biological samples: Localization of peptides and proteins using MALDI-TOF MS. Anal Chem 69, 4751-4760.
Chaurand P, Schwartz SA, Billheimer D, Xu BJ, Crecelius A, and Caprioli RM. (2004). Integrating histology and imaging mass spectrometry. Anal Chem 76, 1145-1155.
Cornett DS, Mobley JA, Dias EC, et al. (2006). A novel histologydirected strategy for MALDI-MS tissue profiling that improves throughput and cellular specificity in human breast cancer. Mol Cell Proteomics 5, 1975-1983.
Djidja MC, Francese S, Loadman PM, et al. (2009). Detergent addition to tryptic digests and ion mobility separation prior to MS/MS improves peptide yield and protein identification for in situ proteomic investigation of frozen and formalin-fixed paraffin-embedded adenocarcinoma tissue sections. Proteomics 9, 2750-2763.
El Ayed M, Bonnel D, Longuespee R, et al. (2010). MALDI imaging mass spectrometry in ovarian cancer for tracking, identifying, and validating biomarkers. Med Sci Monit 16, BR233-245.
Elsner M, Rauser S, Maier S, et al. (2012). MALDI imaging mass spectrometry reveals COX7A2, TAGLN2 and S100-A10 as novel prognostic markers in Barrett's adenocarcinoma. J Proteomics 75, 4693-4704.
Flatley B, Malone P, and Cramer R. (2013). MALDI mass spectrometry in prostate cancer biomarker discovery. Biochim Biophys Acta. Doi:pii: S1570-9639(13)00252-5. 10.1016/j.bbapap .2013.06.015.
Fournier I, Day R, and Salzet M. (2003). Direct analysis of neuropeptides by in situ MALDI-TOF mass spectrometry in the rat brain. Neuro Endocrinol Lett 24, 9-14.
Fournier I, Lemaire R, Wisztorski M, et al. (2006). New insight in sample preparation for MALDI imaging and new developments to approach specific MALDI imaging of the transcriptome. Proc 54rd ASMS Conf Mass Spectrometry, Seattle, Wastington, May 30-June 2.
Fournier I, Wisztorski M, and Salzet M. (2008). Tissue imaging using MALDI-MS: A new frontier of histopathology proteomics. Expert Rev Proteomics 5, 413-424.
Franck J, Arafah K, Barnes A, Wisztorski M, Salzet M, and Fournier I. (2009a). Improving tissue preparation for matrixassisted laser desorption ionization mass spectrometry imaging. Part 1: Using microspotting. Anal Chem 81, 8193-8202.
Franck J, Arafah K, Elayed M, et al. (2009b). MALDI imaging mass spectrometry: State of the art technology in clinical proteomics. Mol Cell Proteomics 8, 2023-2033.
Franck J, Longuespee R, Wisztorski M, et al. (2010). MALDI mass spectrometry imaging of proteins exceeding 30,000 daltons. Med Sci Monit 16, BR293-299.
Gagnon H, Franck J, Wisztorski M, Day R, Fournier I, and Salzet M. (2012). Targeted Mass spectrometry Imaging: Specific Targeting Mass Spectrometry imaging technologies from history to perspective. Prog Histochem Cytochem 47, 133-174.
Gustafsson JO, Eddes JS, Meding S, et al. (2012). Internal calibrants allow high accuracy peptide matching between MALDI imaging MS and LC-MS/MS. J Proteomics 75, 5093-5105.
Jones EA, Deininger SO, Hogendoorn PC, et al. Imaging mass spectrometry statistical analysis. J Proteomics 75, 4960-4989.
Lemaire R, Fournier I, Salzet M, et al. (2005a). Use of conjugates with linkers cleavable by photodissociation or fragmentation for mass spectrometry analysis of tissue sections.US20050687848P.
Lemaire R, Lucot J, Collinet P, et al. (2005). New developments in direct analysis by MALDI mass spectrometry for the study of ovarian cancer. Mol Cell Proteomics 4, S306-S306.
Lemaire R, Lucot JP, Collinet P, Vinatier D, Tabet JC, Salzet M, and Fournier I. (2005b). New developments in direct analyses by MALDI mass spectrometry for study ovarian cancer. Mol Cell Proteomics 4, S305-S308.
Lemaire R, Menguellet SA, Stauber J, et al. (2007a). Specific MALDI imaging and profiling for biomarker hunting and validation: Fragment of the 11S proteasome activator complex, Reg alpha fragment, is a new potential ovary cancer biomarker. J Proteome Res 6, 4127-4134.
Lemaire R, Stauber J, Wisztorski M, et al. (2007b). Tag-mass: Specific molecular imaging of transcriptome and proteome by mass spectrometry based on photocleavable tag. J Proteome Res 6, 2057-2067.
Lemaire R, Wisztorski M, Desmons A, et al. (2006). MALDI-MS direct tissue analysis of proteins: Improving signal sensitivity using organic treatments. Anal Chem 78, 7145-7153.
Longuespee R, Boyon C, Castellier C, et al. (2012a). The C-terminal fragment of the immunoproteasome PA28S (Reg alpha) as an early diagnosis and tumor-relapse biomarker: Evidence from mass spectrometry profiling. Histochem Cell Biol 138, 141-154.
Longuespee R, Boyon C, Desmons A, et al. (2012b). Ovarian cancer molecular pathology. Cancer Metastasis Rev 31, 713-732.
Longuespee R, Gagnon H, Boyon C, et al. (2013). Proteomic analyses of serous and endometrioid epithelial ovarian cancers- Cases studies-Molecular insights of a possible histological etiology of serous ovarian cancer. Proteomics Clin Appl 7, 337-354.
Longuespeé RB, Kerdraon O, Vinatier D, Fournier I, Day R, and Salzet M. (2012). MALDI MSI and ovarian cancer biomarkers. Adv Cancer Manag 211-236.
Lowe KA, Chia VM, Taylor A, et al. (2013). An international assessment of ovarian cancer incidence and mortality. Gynecol Oncol 130, 107-114.
McCombie G, Staab D, Stoeckli M, and Knochenmuss R. (2005). Spatial and spectral correlations in MALDI mass spectrometry images by clustering and multivariate analysis. Anal Chem 77, 6118-6124.
McDonnell LA, Corthals GL, Willems SM, van Remoortere A, van Zeijl RJ, and Deelder AM. (2010). Peptide and protein imaging mass spectrometry in cancer research. J Proteomics 73, 1921-1944.
Meding S, Balluff B, Elsner M, et al. (2012a). Tissue-based proteomics reveals FXYD3, S100A11 and GSTM3 as novel markers for regional lymph node metastasis in colon cancer. J Pathol. Doi: 10.1002/path.4021.
Meding S, Nitsche U, Balluff B, et al. (2012b). Tumor classification of six common cancer types based on proteomic profiling by MALDI imaging. J Proteome Res 11, 1996-2003.
Meding S, and Walch A. (2013). MALDI imaging mass spectrometry for direct tissue analysis. Methods Mol Biol 931, 537-546.
Ray-Coquard I, Chauvin F, Leblanc E, et al. (2012). [PAIR-gynaecology: M-4ulti/interdisciplinary for gynecologic cancer research. Problems needed to be resolved]. Bull Cancer 99, 479-98.
Schober Y, Guenther S, Spengler B, and Rompp A. (2012). Highresolution matrix-assisted laser desorption/ionization imaging of tryptic peptides from tissue. Rapid Commun Mass Spectrom 26, 1141-1146.
Schwamborn K, Krieg RC, Reska M, Jakse G, Knuechel R, and Wellmann A. (2007). Identifying prostate carcinoma by MALDI-Imaging. Int J Mol Med 20, 155-159.
Seeley EH, and Caprioli RM. (2008). Imaging mass spectrometry: Towards clinical diagnostics. Proteomics Clin Appl 2, 1435-1443.
Stauber J, El Ayed M, Wisztorski M, Day R, Fournier I, and Salzet M. (2009). Polymerase chain reaction and immunoassay- matrix assisted laser desorption mass spectrometry using tag-mass technology: New tools to break down quantification limits and multiplexes. Anal Chem 81, 9512-9521.
Stauber J, Lemaire R, Franck J, et al. (2008). MALDI imaging of formalin-fixed paraffin-embedded tissues: Application to model animals of Parkinson disease for biomarker hunting. J Proteome Res 7, 969-978.
Stauber J, Lemaire R, Wisztorski M, et al. (2006). New developments in MALDI imaging mass spectrometry for pathological proteomic studies: Introduction to a novel concept, the specific MALDI imaging. Mol Cell Proteomics 5, S247-S249.
Trede D, Kobarg JH, Oetjen J, Thiele H, Maass P, and Alexandrov T. (2012). On the importance of mathematical methods for analysis of MALDI-imaging mass spectrometry data. J Integr Bioinform 9, 189.
Wisztorski M, Fatou B, Franck J, et al. (2013). Microproteomics by liquid extraction surface analysis: Application to FFPE tissue to study the fimbria region of tubo-ovarian cancer. Proteomics Clin Appl 7, 234-240.
